Clinical study reveals Neauvia fillers' suitability for autoimmune patients

Autoimmune thyroid diseases, notably Hashimoto’s disease, have historically posed challenges in the field of medical aesthetics due to concerns about adverse reactions. However, a recently published study has provided groundbreaking insights into the suitability and safety of Neauvia Stimulate injectable products for patients with autoimmune thyroid conditions. The study’s findings, documented through rigorous histopathological examinations and retrospective analysis of medical records, have significant implications for the field of medical aesthetics.

BACKGROUND AND INNOVATION

Neauvia, a distinguished medical aesthetics company, has pioneered advancements in the industry since its establishment in 2012. This disruptive force in the market has rapidly expanded its global footprint, encompassing production facilities and subsidiaries across numerous countries. With a presence in over 80 countries, Neauvia empowers individuals worldwide to take proactive control of their ageing process through holistic and effective approaches. Neauvia’s polyethylene glycol (PEG) hyaluronic acid (HA) fillers are rooted in innovative cross-linker technology, known as SXT. This technology seamlessly merges HA and PEG polymers, resulting in a unique portfolio boasting exceptional mechanical, rheological, and thermodynamic properties. These attributes, combined with a robust safety profile and high tolerability, facilitate synergistic integration with Neauvia energy-based devices and aesthetic cosmeceuticals, ultimately enhancing clinical and aesthetic outcomes.

STUDY DESIGN AND OBJECTIVES

The study’s primary objective was to evaluate the effects of Neauvia Stimulate – af ormulation of hyaluronic acid crosslinked with polyethylene glycol containing micronised calcium hydroxyapatite – on both local tissues and systemic responses in patients with Hashimoto’s disease. This autoimmune condition often presents contraindications for conventional hyaluronic acid-based fillers and biostimulants using calcium hydroxyapatite.

KEY FINDINGS

The study engaged 15 patients diagnosed with Hashimoto’s thyroiditis, each receiving 2.0 ml of Neauvia Stimulate. Histopathological assessments were conducted before treatment and at intervals of five, 21, and 150 days post-treatment. The results were significant:

• A marked reduction in local inflammatory infiltration at day 21 post-treatment, when compared to baseline

• Substantial decrease in antigen-recognising (CD4) and cytotoxic (CD8) T lymphocytes, indicating immune modulation

• Diminished presence of B-lymphocytes (CD20), further attesting to the treatment’s effectiveness

• Moreover, no correlation was identified between the treatment and levels of anti-TPO and anti-TG antibodies. This aligns with the risk analysis, which reported no alarming symptoms during the observation period.

IMPLICATIONS AND CONCLUSION

The study’s outcomes provide a compelling rationale for the use of Neauvia fillers in patients with Hashimoto’s disease. The observed reduction in inflammatory infiltration and immune cell presence suggests a favourable safety profile and efficacy of Neauvia Stimulate. This study augments the growing body of evidence supporting the clinical viability of PEGylated HA fillers, and by extension, Neauvia’s commitment to advancing safe and effective solutions in the realm of medical aesthetics.

CITATION

Kubik, P.; Gallo, D.; Tanda, M.L.; et al. “Evaluation of the Safety of Neauvia Stimulate Injectable Product in Patients with Autoimmune Thyroid Diseases Based on Histopathological Examinations and Retrospective Analysis of Medical Records.” Gels 2023, 9, 440. https://doi. org/10.3390/gels9060440

To discover more about Neauvia’s portfolio of products and protocols, visit: Email info@neauvia.uk Neauvia UK: neauvia.uk Neauvia Education Channel: neauviachannel.com